Taller height and risk of coronary heart disease and cancer: A within-sibship Mendelian randomization study
- Medical Research Council Integrative Epidemiology Unit, Population Health Sciences, University of Bristol, United Kingdom
- Population Health Sciences, Bristol Medical School, University of Bristol, Barley House, Oakfield Grove, United Kingdom
- K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Norway
- HUNT Research Center, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Norway
- Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Norway
- Department of Endocrinology, Clinic of Medicine, St. Olavs Hospital, Trondheim University Hospital, Norway
Figures
Figure 1
Mendelian randomization within families.
The random allocation of alleles within a parent-offspring quad (two parents and two offspring), initially observed by Mendel, is illustrated. Consider a height influencing genetic variant H where …
Figure 2
Taller height and risk of coronary heart disease and cancer.
The meta-analysis results from four different models used to evaluate the effect of height on coronary heart disease (CHD) and cancer risk are displayed. First, a phenotypic population model with …
Figure 3
Mendelian randomization estimates of the effects of taller height on biomarkers.
The meta-analysis results from population and within-sibship Mendelian randomization analyses estimating the effect of taller height on biomarkers across UK Biobank and HUNT are shown. The estimates …
Tables
Table 1
UK Biobank and HUNT study characteristics.
Information on the UK Biobank and Norwegian HUNT studies, including descriptive of the sibling samples, is given.
| UK Biobank | HUNT | |
|---|---|---|
| Sibling sample:N individuals (N sibships) | 40,275 (19,588) | 38,723 (15,179) |
| Recruitment period:years | 2006–2010 | HUNT2 (1995–97)HUNT3 (2006–08) |
| Year of birth:median (Q1, Q3) | 1950 (1945, 1956) | 1951 (1937, 1963) |
| Sex:male (%) | 42.2 | 48.7 |
| Male height (cm):mean (SD) | 175.7 (6.7) | 177.6 (6.7) |
| Female height (cm):mean (SD) | 162.4 (6.2) | 164.4 (6.3) |
| Coronary heart disease:N cases (% of sample) | 3006 (7.5%) | 6447 (16.6%) |
| Cancer:N cases (% of sample) | 6724 (16.5%) | 2323 (6.0%) |
Table 2
Mendelian randomization (MR) results: change in outcome (SD units), per 1 SD increase in height.
Population and within-sibship MR estimates of height on the eight different outcomes are shown. The presented estimates are from UK Biobank, HUNT, and the combined fixed-effects meta-analysis. The …
| Outcome | Model | UK Biobank | HUNT | Combined | Study heterogeneityp-value |
|---|---|---|---|---|---|
| Systolic blood pressure | Population | –0.044 (–0.074, –0.015) | –0.025 (–0.057, 0.008) | –0.036 (–0.058, –0.014) | 0.38 |
| Within-sibship | –0.077 (–0.137, –0.017) | 0.010 (–0.040, 0.059) | –0.025 (–0.063, 0.013) | 0.03 | |
| High-density lipoprotein cholesterol | Population | –0.039 (–0.070, –0.008) | –0.010 (–0.043, 0.024) | –0.025 (–0.048, –0.003) | 0.21 |
| Within-sibship | –0.038 (–0.096, 0.021) | 0.001 (–0.046, 0.047) | –0.014 (–0.050, 0.022) | 0.31 | |
| Low-density lipoprotein cholesterol | Population | –0.066 (–0.095, –0.036) | –0.065 (–0.098, –0.032) | –0.065 (–0.087, –0.044) | 0.99 |
| Within-sibship | –0.083 (–0.141, –0.025) | –0.014 (–0.061, 0.033) | –0.041 (–0.078, –0.005) | 0.07 | |
| Triglycerides | Population | 0.011 (–0.018, 0.040) | –0.006 (–0.038, 0.027) | 0.004 (–0.018, 0.025) | 0.43 |
| Within-sibship | 0.024 (–0.034, 0.081) | 0.032 (–0.018, 0.082) | 0.028 (–0.009, 0.066) | 0.84 | |
| Glucose | Population | 0.032 (0.005, 0.060) | N/A | 0.032 (0.005, 0.060) | N/A |
| Within-sibship | 0.023 (–0.030, 0.077) | N/A | 0.023 (–0.030, 0.077) | N/A | |
| IGF-1 | Population | –0.005 (–0.035, 0.025) | N/A | –0.005 (–0.035, 0.025) | N/A |
| Within-sibship | –0.045 (–0.093, 0.004) | N/A | –0.045 (–0.093, 0.004) | N/A | |
| Cancer (OR) | Population | 1.12 (1.04, 1.20) | 0.99 (0.88, 1.12) | 1.09 (1.02, 1.16) | 0.089 |
| Within-sibship | 1.21 (1.03, 1.42) | 1.12 (0.90, 1.39) | 1.18 (1.03, 1.34) | 0.57 | |
| Coronary heart disease (OR) | Population | 0.94 (0.84, 1.04) | 0.88 (0.80, 0.96) | 0.90 (0.84, 0.96) | 0.33 |
| Within-sibship | 0.81 (0.65, 1.02) | 0.88 (0.77, 1.00) | 0.86 (0.77, 0.97) | 0.55 |
Additional files
-
Supplementary file 1
Supplementary tables.
(a) contains the different variables and codes used to define coronary heart disease, all cancers, and subset of cancer disease outcomes in UK Biobank. (b) contains population and within-sibship associations between measured height and the eight different outcomes. Presented estimates are from UK Biobank, HUNT, and the combined fixed-effects meta-analysis. The heterogeneity p-value refers to the difference between the UK Biobank and HUNT estimates. (c) contains population and within-sibship associations between the height polygenic score (PGS) and the eight different outcomes. Estimates are presented from UK Biobank and HUNT. (d) contains population and within-sibship associations between three height-related measures (leg length, trunk length, and leg/trunk ratio) and cancer and coronary heart disease from UK Biobank. Height associations are presented for comparison. (e) contains population and within-sibship phenotypic and Mendelian randomization estimates for height on a set of cancer subtypes with limited prior evidence for association with height. Estimates for the ‘all cancers’ outcome are included for comparison. This analysis was conducted in UK Biobank only.
- https://cdn.elifesciences.org/articles/72984/elife-72984-supp1-v2.docx
-
Transparent reporting form
- https://cdn.elifesciences.org/articles/72984/elife-72984-transrepform1-v2.docx
